A Phase 1 interventional study of Glycopyrrolate + Formoterol and Glycopyrrolate in COPD, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-29.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 54th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 1, and was the 18th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A.: 5 open now, 5 under way, none of them phase 3. Of 62 finished, 7 (11%) have results posted.
Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 39th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2011, is one of 21 in phase 1, and was the 14th registered.
Chiesi Farmaceutici S.p.A.’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2004.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 68 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This study will be carried out in healthy volunteers with the primary objective to evaluate the pharmacokinetic interaction between Glyco and Formoterol administered using a pressurised metered dose inhaler (pMDI).
Inclusion Criteria:
Drug: Formoterol
Drug: Glycopyrrolate
Drug: Placebo
Drug: Glycopyrrolate + Formoterol
Drug pages: Glycopyrrolate · Formoterol
glycopyrrolate pMDI + formoterol pMDI
glycopyrrolate pMDI
formoterol pMDI
placebo pMDI
Pharmacokinetics: formoterol and glyco AUC0-t
Area under the plasma concentration curve observed from administration up to the last measurable concentration.
Time frame: from pre-dose to 32 hours after administration
Pharmacokinetics: formoterol and glyco Cmax
Maximum plasma concentration
Time frame: from pre-dose to 32 hours after administration
Additional pharmacokinetic variables
Plasma Glyco AUC0-30min, AUC0-32h, AUC0-inf, tmax and t1/2 - Plasma Formoterol AUC0-30min, AUC0-24h, AUC0-inf, tmax and t1/2.
Time frame: from pre-dose to 32 hours post dose
Serum potassium
Serum potassium Cmin, tmin and AUC0-24h
Time frame: From pre-dose to 24 hours after administration
Plasma glucose
Plasma glucose Cmax, tmax and AUC0-24h
Time frame: from pre-dose to 24 hours after administration
Lung function
FEV1 in order to assess potential occurrence of paradoxical bronchospasm
Time frame: from pre-dose to 1 hour after administration
Vital signs
heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP).
Time frame: from pre-dose to 24 hours after administration
ECG
12-lead ECG parameters: HR, RR, PR, QRS, QT, QTcB, QTcF
Time frame: from pre-dose to 24 hours after administration
The record gives a start of May 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glycopyrrolate · Formoterol
Pulmonary Disease, Chronic Obstructive →